FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi’s focus in immunology includes moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, inadequately controlled chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE), polymyalgia rheumatica (PMR), prurigo nodularis (PN), and moderate-to-severe rheumatoid arthritis (RA).

Latest News from Sanofi

Phase 3 data for sarilumab in patients with polymyalgia published in NEJM

Educational Resources

Asthma

Comparative Effectiveness of Current Asthma Biologics in the United States
A summary of recent, independent, real world evidence and indirect treatment comparisons among current asthma biologics approved in the US. This resource summarizes study methodology and key findings of asthma biologic comparison studies.

Associated Clinical Guidelines and Recommendations

GINA | Global Initiative for Asthma | 2023
NHLBI | National Heart, Lung, and Blood Institute | 2020

Atopic Dermatitis

Current Understanding and Disease Management of Atopic Hand and Foot Dermatitis
A resource discussing clinical features, epidemiology, disease burden, pathophysiology, and disease management of Hand and Foot Atopic Dermatitis.

CRSwNP Disease State Overview Deck
A resource discussing clinical features, epidemiology, disease burden, pathophysiology, and disease management of Chronic Rhinosinusitis with Nasal Polyposis.

PRO1 Dupilumab COPD NOTUS vs BOREAS Infographic
A top-line, side-by-side summary of key data from NOTUS and BOREAS, based on the NOTUS interim results press release and the BOREAS primary data publication evaluating dupilumab use in COPD.

PRO1 MVO COPD Value Proposition Deck
A presentation providing an overview of the COPD pathophysiology, disease burden, management, and economic burend, as well as the data from the dupilumab trials in COPD, NOTUS and BOREAS.

Associated Clinical Guidelines and Recommendations
AAD | American Academy of Dermatology | 2023
AAAAI/ACAAI | American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology | 2012

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease: Disease State Overview
A resource discussing clinical features, epidemiology, disease burden, pathophysiology, and disease management COPD.

Current Understanding and Disease Management of Chronic Obstructive Pulmonary Disease
This deck provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) disease state, including clinical presentation, burden, pathophysiology, and current management/guidelines.

Dupilumab Chronic Obstructive Pulmonary Disease Phase 3 BOREAS Data
This slide deck provides a review of the BOREAS primary publication, which includes study design, outcomes data, safety data, and study limitations.

BOREAS: NCT03930732; Link to Publication

Dupilumab Chronic Obstructive Pulmonary Disease Phase 3 BOREAS Data (Infographic)
This infographic provides a top-line summary of data published in the BOREAS manuscript, discussing study design, outcomes data, safety data, and study limitations evaluating dupilumab for Chronic Obstructive Pulmonary Disease.

BOREAS: NCT03930732; Link to Publication

GOLD | Global Initiative for Chronic Obstructive Lung Disease | 2023

Chronic Rhinosinusitis with Nasal Polyps

Associated Clinical Guidelines and Recommendations
AAAAI/ACAAI | American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology | 2023
Orlandi et al. | International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS) | 2021
Han et al. | US Multidisciplinary Consensus on a Stepwise Treatment Algorithm | 2021

Eosinophilic Esophagitis

Dupilumab Eosinophilic Esophagitis Phase 3 KIDS Data
An overview of the Phase 3 dupilumab Eosinophilic Esophagitis clinical trial program in patients 1 – 11 years of age.

EoE KIDS: NCT04394351

Associated Clinical Guidelines and Recommendations
AGA/JTF | American Gastroenterological Association/Joint Task Force on Allergy-Immunology Practice Parameters | 2020

Polymyalgia Rheumatica

Polymyalgia Rheumatica
A presentation providing an overview of polymyalgia rheumatica (PMR) and its management, including impact on quality of life, challenges associated with diagnosis, and the unmet needs resulting from currently available treatment options, in which glucocorticoids play a central role. The presentation also reviews the pathophysiology of PMR and the rationale for IL-6 inhibition as a potential future treatment.

Associated Clinical Guidelines and Recommendations
EULAR/ACR | European League Against Rheumatism/American College of Rheumatology | 2015
Dejaco et al. | International Treat-to-Target Recommendations | 2023

Prurigo Nodularis

Current Understanding and Disease Management of Prurigo Nodularis
A presentation providing a disease state overview of prurigo nodularis for a payer audience, including clinical presentation, epidemiology, burden, pathophysiology, and disease management.